Latest Breaking News On - ஜோர்டானா கோஹன் - Page 1 : comparemela.com

January 13, 2021 Another randomized trial, REPLACE COVID, indicates that patients already taking ACE inhibitors and ARBs when they’re hospitalized for COVID-19 should continue to do so, supporting recommendations from international CV societies. When it came to outcomes including all-cause death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during hospitalization, there were no differences between patients who continued versus discontinued their renin-angiotensin-aldosterone-system (RAAS) inhibitors after they were admitted, researchers report in a study published online last week in the Lancet Respiratory Medicine. More of TCTMD s coverage on our COVID-19 hub. Considering these findings and those from the BRACE CORONA trial, presented last year at the virtual European Society of Cardiology Congress, the message is simple, according to senior author Julio Chirinos, MD, PhD (University of Pennsylvania, Philade

United statesUniversity of pennsylvaniaJordana cohenRenato lopesJulio chirinosBryan williamsPhd duke universityEuropean society of cardiology congressMd university college londonMd university of pennsylvaniaPhd university of pennsylvaniaLancet respiratoryEuropean societyCardiology congressSequential organ failure assessmentGood clinical practice